These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32773110)
1. Regulation of TP73 transcription by Hippo-YAP signaling. Wen Z; Wang Y; Qi S; Ma M; Li J; Yu FX Biochem Biophys Res Commun; 2020 Oct; 531(2):96-104. PubMed ID: 32773110 [TBL] [Abstract][Full Text] [Related]
2. RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73. Papaspyropoulos A; Bradley L; Thapa A; Leung CY; Toskas K; Koennig D; Pefani DE; Raso C; Grou C; Hamilton G; Vlahov N; Grawenda A; Haider S; Chauhan J; Buti L; Kanapin A; Lu X; Buffa F; Dianov G; von Kriegsheim A; Matallanas D; Samsonova A; Zernicka-Goetz M; O'Neill E Nat Commun; 2018 Jan; 9(1):424. PubMed ID: 29382819 [TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic significance of YAP, TAZ, TEAD4 and p73 in human laryngeal cancer. Tsinias G; Nikou S; Mastronikolis N; Bravou V; Papadaki H Histol Histopathol; 2020 Sep; 35(9):983-995. PubMed ID: 32378727 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Kim M; Kim T; Johnson RL; Lim DS Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714 [TBL] [Abstract][Full Text] [Related]
5. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Lin Z; Guo H; Cao Y; Zohrabian S; Zhou P; Ma Q; VanDusen N; Guo Y; Zhang J; Stevens SM; Liang F; Quan Q; van Gorp PR; Li A; Dos Remedios C; He A; Bezzerides VJ; Pu WT Dev Cell; 2016 Nov; 39(4):466-479. PubMed ID: 27720608 [TBL] [Abstract][Full Text] [Related]
6. IQGAP1 Binds to Yes-associated Protein (YAP) and Modulates Its Transcriptional Activity. Sayedyahossein S; Li Z; Hedman AC; Morgan CJ; Sacks DB J Biol Chem; 2016 Sep; 291(37):19261-73. PubMed ID: 27440047 [TBL] [Abstract][Full Text] [Related]
7. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421 [TBL] [Abstract][Full Text] [Related]
8. MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. Alam M; Bouillez A; Tagde A; Ahmad R; Rajabi H; Maeda T; Hiraki M; Suzuki Y; Kufe D Mol Cancer Res; 2016 Dec; 14(12):1266-1276. PubMed ID: 27658423 [TBL] [Abstract][Full Text] [Related]
9. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865 [TBL] [Abstract][Full Text] [Related]
10. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099 [TBL] [Abstract][Full Text] [Related]
11. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868 [TBL] [Abstract][Full Text] [Related]
12. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]
13. Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor. Vargas RE; Duong VT; Han H; Ta AP; Chen Y; Zhao S; Yang B; Seo G; Chuc K; Oh S; El Ali A; Razorenova OV; Chen J; Luo R; Li X; Wang W EMBO J; 2020 Jan; 39(1):e102406. PubMed ID: 31782549 [TBL] [Abstract][Full Text] [Related]
14. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ. Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Chen M; Wang M; Xu S; Guo X; Jiang J Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204 [TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ for cancer therapy: opportunities and challenges (review). Guo L; Teng L Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178 [TBL] [Abstract][Full Text] [Related]
17. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway. Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577 [TBL] [Abstract][Full Text] [Related]
18. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Zhao B; Kim J; Ye X; Lai ZC; Guan KL Cancer Res; 2009 Feb; 69(3):1089-98. PubMed ID: 19141641 [TBL] [Abstract][Full Text] [Related]
19. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Chen L; Chan SW; Zhang X; Walsh M; Lim CJ; Hong W; Song H Genes Dev; 2010 Feb; 24(3):290-300. PubMed ID: 20123908 [TBL] [Abstract][Full Text] [Related]
20. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ). Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]